<span item_type="fundamental" item_id="ceaa064b1a8b8ef330e90f60363b591d" counter_id="ST/US/LEXXW" env="prod"></span><span item_type="announcement" item_id="538106814961095425" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 531.92 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.53.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>IP Licensing</strong>: Revenue for the nine months ended May 31, 2025, was $522,000, compared to $373,990 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li><li><strong>B2B Product</strong>: Revenue for the nine months ended May 31, 2025, was $9,923, compared to $5,388 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the nine months ended May 31, 2025, was $9,214,206, compared to $3,622,083 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the nine months ended May 31, 2025, were $9,721,343, compared to $3,925,522 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was $7,807,889 for the nine months ended May 31, 2025, compared to $3,067,344 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li><li><strong>Free Cash Flow</strong>: The net change in cash for the period was - $1,908,124 for the nine months ended May 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development</strong>: R&amp;D expenses increased significantly to $6,356,637 for the nine months ended May 31, 2025, from $1,393,359 for the same period in 2024, primarily due to clinical trials and drug manufacturing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Lexaria plans to continue its R&amp;D efforts, particularly in the area of DehydraTECH formulations for GLP-1 drugs and hypertension treatment. The company anticipates increased expenditures in these areas as it progresses with clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring potential collaborations or strategic partnerships to fund its operations and R&amp;D activities, given the substantial doubt about its ability to continue as a going concern without additional financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1348362/000164033425001195/lxrp_10q.htm"></span></li></ul>

LEXARIA BIOSCIENCE CORP C/WTS 14/01/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 531.92 K